EverHint — Pullback Plays (with Insider, Earnings & News Overlays) - November 11, 2025
November 11, 2025
What this signal is (quick)
We’re looking for strong names pulling back toward support while overall uptrends remain intact. The idea: identify constructive retracements (often after breakouts or sharp runs) where volume thrust, % of 52-week high, and short-term return gauges hint at buy-the-dip potential—without front-running breakdowns.
Today’s signals use end-of-day data for 2025-11-11, and this scanner remains experimental while we refine performance tracking.
How we ranked today (reader version)
- Factors shown: Volume Thrust, % of 52-W High, short-term return differentials (r10_2, r21_3, rs_21), plus proximity to moving averages (MA10/21/50/200).
- We display the consolidated Score from the file; no extra overlays were used.
📈 Buy-Side Candidates — Pullback Plays
| Rank | Ticker | Company | Sector | Last ($) | Volume Thrust | % of 52-W High | RS-21 | Score |
|---|---|---|---|---|---|---|---|---|
| 1 | REAL | The RealReal, Inc. | Consumer Cyclical | 15.48 | 5.13 | 100.00% | 0.476 | 0.30 |
| 2 | VSAT | Viasat, Inc. | Technology | 38.11 | 1.67 | 95.71% | 0.066 | 0.15 |
| 3 | CRNX | Crinetics Pharmaceuticals, Inc. | Healthcare | 42.94 | 1.57 | 93.53% | −0.062 | 0.00 |
Field notes
- Volume Thrust >1 often marks accumulation after a dip.
- % of 52-W High near 100% indicates shallow pullbacks in strong trends.
- RS-21 is a 21-day relative-strength style gauge from the file.
Recent Headlines (same-day or very recent)
- REAL — The RealReal: Reported Q3 2025 with record GMV and stronger profitability; shares rallied on outlook. (The RealReal Investor)
- VSAT — Viasat: Q2 FY26 results posted Nov 7; ViaSat-3 F2 launch attempts were scrubbed Nov 6 with timing update pending; trade press flags modest sales growth led by Defense. (Viasat.com)
- CRNX — Crinetics: Inducement grants announced Nov 10; context: FDA approved oral acromegaly pill last month. (Crinetics)
📉 Sell-Side Signals — (none in today’s file)
No down-trend pullbacks were flagged by the provided data.
Field notes
Pullback failures often start with low volume bounces that roll over below MA21/MA50. If a name re-tests lows on rising volume, treat as caution.
Vlad’s Take (EverHint)
Three-name list, all near highs—classic “shallow dip” profile. I’d scale entries on further weakness into MA10/MA21 rather than chasing strength, and respect prior swing lows for stops. News flow is supportive for REAL and mixed-to-catalyst-pending for VSAT; CRNX has fresh HR/ops items with recent FDA tailwind.
Today’s rotation snapshot: Consumer Cyclical & Tech show constructive pullbacks; select Biotech steady after prior run.
Independent research. No hype, no pumps, no paid promotions — just clean, data-driven signals and concise context.